Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial
暂无分享,去创建一个
A. Schwarer | D. White | T. Hughes | S. Branford | A. Grigg | C. Slader | D. Yeung | M. Hertzberg | C. Arthur | D. Ross | C. Forsyth | D. Hiwase | M. Osborn | Y. Kwan | R. Filshie | S. Issa | A. Mills | M. Kornhauser